These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20970022)

  • 21. Salivary glands: a new player in phosphorus metabolism.
    Savica V; Calò LA; Santoro D; Monardo P; Santoro G; Muraca U; Davis PA; Bellinghieri G
    J Ren Nutr; 2011 Jan; 21(1):39-42. PubMed ID: 21195917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of depot oral cholecalciferol treatment on secondary hyperparathyroidism in stage 3 and stage 4 chronic kidney diseases patients.
    Dogan E; Erkoc R; Sayarlioglu H; Soyoral Y; Dulger H
    Ren Fail; 2008; 30(4):407-10. PubMed ID: 18569914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Phosphate binders for therapy of hyperphosphatemia causing secondary hyperparathyroidism and renal osteodystrophy in patients with chronic renal failure].
    Kanagawa S; Yosikawa Y; Dohi Y
    Nihon Rinsho; 1991 Dec; 49 Suppl():770-4. PubMed ID: 1808348
    [No Abstract]   [Full Text] [Related]  

  • 24. Phosphate-binding capacities of calcium and aluminum formulations.
    Lau AH; Kuk JM; Franson KL
    Int J Artif Organs; 1998 Jan; 21(1):19-22. PubMed ID: 9554821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The treatment of hyperphosphataemia in CKD: calcium-based or calcium-free phosphate binders?
    Cozzolino M; Mazzaferro S; Brandenburg V
    Nephrol Dial Transplant; 2011 Feb; 26(2):402-7. PubMed ID: 21079194
    [No Abstract]   [Full Text] [Related]  

  • 26. Niacin and Chronic Kidney Disease.
    Taketani Y; Masuda M; Yamanaka-Okumura H; Tatsumi S; Segawa H; Miyamoto K; Takeda E; Yamamoto H
    J Nutr Sci Vitaminol (Tokyo); 2015; 61 Suppl():S173-5. PubMed ID: 26598845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can a dietitian help prevent renal bone disease in the hemodialysis patient?
    Harum P
    Nephrol News Issues; 1990 Sep; 4(9):35, 37, 42. PubMed ID: 2402318
    [No Abstract]   [Full Text] [Related]  

  • 28. Function and effect of bone morphogenetic protein-7 in kidney bone and the bone-vascular links in chronic kidney disease.
    Mathew S; Davies M; Lund R; Saab G; Hruska KA
    Eur J Clin Invest; 2006 Aug; 36 Suppl 2():43-50. PubMed ID: 16884397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Calcium balance in dialysis is best managed by adjusting dialysate calcium guided by kinetic modeling of the interrelationship between calcium intake, dose of vitamin D analogues and the dialysate calcium concentration.
    Gotch F; Levin NW; Kotanko P
    Blood Purif; 2010; 29(2):163-76. PubMed ID: 20093823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are calcium-based phosphate binders ever preferable in dialysis patients?
    Jain N; Reilly RF
    Semin Dial; 2014; 27(3):269-72. PubMed ID: 24620781
    [No Abstract]   [Full Text] [Related]  

  • 31. [Renal osteodystrophy (3); its treatment in dialysis patients].
    Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
    Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Renal osteodystrophy in children. Pathogenic role and modalities of control of phosphate retention].
    Boudailliez B; Bony-Trifunovic H; Berquin P; Piussan C; Fournier A
    Arch Fr Pediatr; 1991 Apr; 48(4):279-86. PubMed ID: 2069483
    [No Abstract]   [Full Text] [Related]  

  • 33. Hyperparathyroidism in the maintenance dialysis patient.
    Glassford DM; Remmers AR; Sarles HE; Lindley JD; Scurry MT; Fish JC
    Surg Gynecol Obstet; 1976 Mar; 142(3):328-32. PubMed ID: 1251311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyperphosphatemia in renal failure.
    Robb M
    RN; 2008 Dec; 71(12):26-30; quiz 31. PubMed ID: 19108567
    [No Abstract]   [Full Text] [Related]  

  • 35. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
    Shigematsu T;
    Ther Apher Dial; 2010 Feb; 14(1):12-9. PubMed ID: 20438515
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Renal osteodystrophy (2): its treatment in renal insufficiency before dialysis].
    Hottelart C; Bako G; Oprisiu R; Georgita A; Presne C; Sarraj A; Morinière P; el Esper N; Fournier A
    Nephrologie; 2000; 21(6):275-82. PubMed ID: 11117106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. When is Vitamin D contraindicated in dialysis patients?
    Lewin E; Olgaard K
    Semin Dial; 2009; 22(3):240-2. PubMed ID: 19572998
    [No Abstract]   [Full Text] [Related]  

  • 38. Phosphate control in end-stage renal disease: barriers and opportunities.
    Waheed AA; Pedraza F; Lenz O; Isakova T
    Nephrol Dial Transplant; 2013 Dec; 28(12):2961-8. PubMed ID: 23901051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. III. Clinical algorithms on renal osteodystrophy.
    Nephrol Dial Transplant; 2000; 15 Suppl 5():39-57. PubMed ID: 11073276
    [No Abstract]   [Full Text] [Related]  

  • 40. Vitamin D3 withdrawal in hemodialysis patients with adynamic bone disease.
    Kondo M; Hyodo T; Sakai T
    Nephron; 1998 Sep; 80(1):89. PubMed ID: 9730714
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.